Dear Sir / Ma’am,
As per the global Type 1 Diabetes Index, T1D in India is growing at 6.7% each year compared to 4.4% growing rate of Type 2 diabetes.
RSSDI and Sanofi’s Social impact initiative has been delivering positive outcomes for Type 1 Diabetes. As part of this program, more than 1300 young T1D patients have been enrolled nationwide, including 76 from Kerala.
Below mentioned is some more information about the program, for your reference: The Social Impact Program for Type 1 Diabetes has delivered positive outcomes in reducing hypoglycemia and hyperglycemia, greatly improving care and diagnosis for those affected by this autoimmune chronic condition, especially among pediatric and young adult populations. Individuals with Type 1 Diabetes encounter numerous challenges, including a shortage of specialized healthcare providers and educators trained to treat and manage T1D. Additionally, they face issues such as low public awareness, socioeconomic burdens, and limited access to adequate healthcare facilities, particularly in semi-urban and rural areas. Delayed diagnosis, inadequate cold-chain management for insulin, and insufficient patient and caregiver education further compound these complexities. Furthermore, Type 1 diabetes often leads to social isolation, particularly among girls. This Social Impact Program by RSSDI (India’s leading diabetes research organization) and Sanofi provides free insulin, syringes, lancets, and glucose strips to patients, while also focusing on raising awareness and training healthcare providers and educators to better serve patients and caregivers.
Please find the press release attached.
Kindly revert on this mail, if you take the coverage forward. Feel Free to reach out to me for any details or doubts. Thankyou.
Regards,
Drishti Gupta
Adfactors PR| M: +91 84482 44139 | T: 011 40565100
Website | Blog | Facebook | Twitter | LinkedIn | Instagram
Disclaimer: The information in this email is confidential and is intended solely for the addressee(s). Access to this email by anyone else is unauthorized. If you are not an intended recipient, you must not read, use or disseminate the information contained in this email.